Welcome to our dedicated page for Lifemd news (Ticker: LFMDP), a resource for investors and traders seeking the latest updates and insights on Lifemd stock.
LifeMD, Inc. issues news on its virtual primary care and pharmacy services business, including telemedicine, laboratory access, pharmacy fulfillment, and specialized treatment programs across primary care, men's and women's health, weight management, and hormone therapy. Updates often cover its digital care platform, affiliated medical group, pharmacy infrastructure, patient care center, and branded GLP-1 access within weight management.
For LFMDP, company news also includes dividends on LifeMD's 8.875% Series A Cumulative Perpetual Preferred Stock. Other recurring items include financial results, investor conference participation, credit facilities, and executive leadership changes.
CEO Schreiber to discuss changes made possible via proprietary virtual care platforms
LifeMD, a leading telehealth company (NASDAQ: LFMD), announced that CEO Justin Schreiber will participate in a panel at the LifeSci Partners Corporate Access Event, happening virtually from January 5-7, 2022. Schreiber will discuss how LifeMD's virtual care technology is transforming healthcare to improve affordability and patient outcomes. The panel, titled 'Telehealth & Digital Medicine: At a Crossroads of Virtual Care,' is scheduled for January 6 at 8:30 am ET. Interested parties can register for the webcast to view the discussion.
On December 23, 2021, LifeMD announced a cash dividend of $0.622483 per share for its 8.875% Series A Cumulative Perpetual Preferred Stock (LFMDP), payable on January 14, 2022. The dividend will be distributed to shareholders of record on January 4, 2022. LifeMD is a growing telehealth company providing virtual medical care across the U.S., emphasizing affordable treatment and home delivery of prescriptions.